Introduction: Although hospitals are key health service providers, their financial ties to drug companies have been rarely scrutinised. In developing this body of work, we examine industry payments for non-research activities to National Health Service (NHS) trusts – hospital groupings providing publicly funded secondary and tertiary care in England. Methods: We extracted data from the industry-run Disclosure UK database, analysing payment distribution descriptively and identifying trends in medians with the Jonckheere-Terpstra test. The payment value and number per NHS trust were explained using random effects models. Results: Between 2015 and 2018, 116 companies reported paying £60,253,421.86 to 235 trusts. As a share of payments to all healthcare organisations the number of payments to trusts rose from 38.64% to 39.48%, but their value dropped from 33.01% to 23.61%. While the number of all payment types rose, fees for service and consultancy and contributions to costs of events increased by 61.55% and 29.43%, respectively. The median payment values decreased significantly for trusts overall, including those with lower autonomy from central government; providing acute services; and from four of the eight regions of England. The random effects model showed that trusts with all other service profiles received a significantly lower value of payments on average than acute trusts; and trusts from East England received significantly less than those from London. However, trusts enjoying greater autonomy from government did not receive significantly more payments than others. Trusts also received significantly lower (but not fewer) payments in 2018 than in 2015. Conclusion: NHS trusts were losing importance as funding targets relative to other healthcare organisations. Industry payment strategies shifted towards engaging with NHS trusts using events sponsorship, consultancies, and smaller payments. Industry prioritised payments to trusts with specific service and geographical profiles. More granular disclosure is necessary to understand the role of corporate funding across the health system.

Data from NHS trusts about X-Rays, computed tomography (CT) and magnetic resonance imaging (MRI) scans.

BackgroundThere is limited evidence about how vocational rehabilitation (VR) for people with multiple sclerosis (MS) can be delivered through the United Kingdom’s (UK) National Health Service (NHS) and how it works.AimTo understand the mechanisms and context for implementing a VR intervention for people with MS in the NHS and develop an explanatory programme theory.MethodsA realist evaluation, including a review of evidence followed by semi-structured interviews. A realist review about VR for people with MS in the NHS was conducted on six electronic databases (PubMed, MEDLINE, PsychINFO, Web of Science, CINAHL, and EMBASE) with secondary purposive searches. Included studies were assessed for relevance and rigour. Semi-structured interviews with people with MS, employers, and healthcare professionals, were conducted remotely. Data were extracted, analysed, and synthesised to refine the programme theory and produce a logic model.ResultsData from 13 studies, and 19 interviews (10 people with MS, five employers, and four healthcare professionals) contributed to producing the programme theory. The resulting programme theory explains the implementation of VR in the NHS for MS populations, uncovering the complex interplay between the healthcare and employment sectors to influence health and employment outcomes. VR programmes that offer timely support, tailored to the needs of the person with MS, and that support and empower the employee beyond the healthcare context are most likely associated with improved employment outcomes, for example, job retention.ConclusionEmbedding VR support within the NHS requires substantial cultural and organisational change (e.g., increased staff numbers, training, and awareness about the benefits of work). This study emphasises the need to routinely identify people with MS at risk of job loss and follow a collaborative approach to address employment issues. This realist evaluation provides insight on how to improve the quality of care available to people with MS.

The iCARE SDE is a cloud-based, big data analytics platform sitting within Imperial College Healthcare NHS Trust (ICHT) NHS infrastructure. This, combined with the iCARE Team’s robust method of data de-identification, make the Environment an incredibly secure platform. The fact that it can be accessed remotely using the Trust’s Virtual Desktop Infrastructure means that researchers can perform their work remotely and are therefore not constrained by location. (imperial.dcs@nhs.net)

The iCARE SDE enables clinicians, researchers and data scientists to access large-scale, highly curated databases for the purposes of research, clinical audit and service evaluation. The iCARE SDE enables advanced data analytics through a scalable virtual infrastructure supporting Azure Machine Learning, Python, R and STATA and a large variety of snowflake SQL tooling.

The main iCARE data model is a HRA REC approved database covering all routinely captured information from Imperial College Healthcare Trust (ICHT) Electronic Health Record and 39 linked (at the patient-level) clinical and non-clinical systems. It contains data for all patients from 2015 onwards and is updated weekly as a minimum, and close to real-time when required. It includes inpatient, outpatient, A&E, pathology, cancer, imaging treatments, e-prescribing, procedures, clinical notes, Consent, clinical trials, tissue bank samples, Patient safety and incidents, Patient experience, Staffing and environment data.

Data can also be linked to primary care data for the 2.8million population in Northwest London, HRA REC approved, Whole Systems Integrated Care (WSIC) hosted database and other health and social care providers when approved.

On a project-by-project basis the model can be expanded to curate and include new data (including multi-modality data), that is either captured routinely or through approved research and clinical trials. There are streamlined processes to approve and curate new data (imperial.dataaccessrequest@nhs.net) and data will always remain hosted in the SDE.

The National Highway System (NHS) dataset and its geometries was updated on March 27, 2025 from the Federal Highway Administration (FHWA) and is part of the U.S. Department of Transportation (USDOT)/Bureau of Transportation Statistics (BTS) National Transportation Atlas Database (NTAD). The National Highway System consists of roadways important to the nation’s economy, defense, and mobility. The National Highway System (NHS) includes the following subsystems of roadways: Interstate - The Eisenhower Interstate System of highways, Other Principal Arterials - highways in rural and urban areas which provide access between an arterial and a major port, airport, public transportation facility, or other intermodal transportation facility, Strategic Highway Network (STRAHNET) - a network of highways which are important to the United States’ strategic defense policy and which provide defense access, continuity and emergency capabilities for defense purposes, Major Strategic Highway Network Connectors - highways which provide access between major military installations and highways which are part of the Strategic Highway Network, Intermodal Connectors - highways providing access between major intermodal facilities and the other four subsystems making up the National Highway System. A specific highway route may be on more than one subsystem. A data dictionary, or other source of attribute information, is accessible at https://doi.org/10.21949/1529838

Please provide the following information under FOI law full schedule of uk databases used to check eligibility for Health Insurance Card eg NI, passport, register of births number of applications for HI Card received april 22-april 23 number of applications rejected due to lack of proof of eligibility april 22-april 23 number of people required to provide further proof following application NHS definition of legal criteria for eligibility for Health Insurance Card Your request was received on 16 August 2023 and I am dealing with it under the terms of the Freedom of Information Act 2000. On 3 December 2023 you clarified the following: 1) When assessing UK Global Health Insurance Card applications does the Authority have access to UK Government records? For example Registration of Births, National Insurance, EU Settlement Scheme records, UK Passport Office Records, DVA Records of Driving Licences? 2) Please give me the number of applications for UK Global Health Insurance Card applications in the last financial year. Please also indicate the number that were approved and the number rejected due to insufficient proof of residency. On 27th December 2023 you clarified the following: 5) I can confirm I want the information for EHIC, UK EHIC and UK GHIC. Response Question 1 When assessing UK Global Health Insurance Card applications, the NHSBSA has access to some UK Government records, such as EU settlement Scheme records. The NHSBSA does not have access to National Insurance records, Registration of Births, UK Passport Office Records or DVA Records. UK Global Health Insurance Card applications are based on a residency system and the NHSBSA will use third party data provider Equifax to establish UK residency. This is stated in our Privacy Notice. https://www.nhsbsa.nhs.uk/our-policies/privacy/overseas-healthcare-services-privacy-notice#:~:text=You%20have%20the%20right%20to,it%20for%20longer%20than%20necessary Question 2 There were 6,510,849 UK Global Health Insurance Card applications in the last financial year. Question 3 and 4 6,016,310 applications were approved and 145,876 were rejected because we were unable to establish proof of residency. The remaining applications were either rejected for other reasons, or we have not yet finished dealing with them. Question 5 The following links provide definitions of legal criteria for eligibility for UK GHIC and UK EHIC: • https://faq.nhsbsa.nhs.uk/knowledgebase/article/KA-26813 • https://www.nhs.uk/using-the-nhs/healthcare-abroad/apply-for-a-free-uk-global-health-insurance-card-ghic/ Please note that we do not issue EHIC anymore as that card has been replaced by the UK EHIC.

The Child Health System in Wales; includes birth registration and monitoring of child health examinations and immunisations.

The Child Health System in Wales; includes birth registration and monitoring of child health examinations and immunisations.

The dataset brings together data from local Child Health System databases which are held by NHS Trusts and used by them to administer child immunisation and health surveillance programmes.

The dataset contains all children born, resident or treated in Wales and born after 1987.

Attendance information for all hospital outpatient appointments. The data are collected and coded at each hospital. Administrative information is collected from the central PAS (Patient Administrative System), such as specialty of care, appointment date and attendance status.

This dataset contains all scheduled outpatient appointments, including those where the patient failed to attend.

Abstract copyright UK Data Service and data collection copyright owner.

Background:
The Millennium Cohort Study (MCS) is a large-scale, multi-purpose longitudinal dataset providing information about babies born at the beginning of the 21st century, their progress through life, and the families who are bringing them up, for the four countries of the United Kingdom. The original objectives of the first MCS survey, as laid down in the proposal to the Economic and Social Research Council (ESRC) in March 2000, were:

• to chart the initial conditions of social, economic and health advantages and disadvantages facing children born at the start of the 21st century, capturing information that the research community of the future will require
• to provide a basis for comparing patterns of development with the preceding cohorts (the National Child Development Study, held at the UK Data Archive under GN 33004, and the 1970 Birth Cohort Study, held under GN 33229)
• to collect information on previously neglected topics, such as fathers' involvement in children's care and development
• to focus on parents as the most immediate elements of the children's 'background', charting their experience as mothers and fathers of newborn babies in the year 2000, recording how they (and any other children in the family) adapted to the newcomer, and what their aspirations for her/his future may be
• to emphasise intergenerational links including those back to the parents' own childhood
• to investigate the wider social ecology of the family, including social networks, civic engagement and community facilities and services, splicing in geo-coded data when available

Additional objectives subsequently included for MCS were:

• to provide control cases for the national evaluation of Sure Start (a government programme intended to alleviate child poverty and social exclusion)
• to provide samples of adequate size to analyse and compare the smaller countries of the United Kingdom, and include disadvantaged areas of England

Further information about the MCS can be found on the Centre for Longitudinal Studies web pages.

The content of MCS studies, including questions, topics and variables can be explored via the CLOSER Discovery website.

The first sweep (MCS1) interviewed both mothers and (where resident) fathers (or father-figures) of infants included in the sample when the babies were nine months old, and the second sweep (MCS2) was carried out with the same respondents when the children were three years of age. The third sweep (MCS3) was conducted in 2006, when the children were aged five years old, the fourth sweep (MCS4) in 2008, when they were seven years old, the fifth sweep (MCS5) in 2012-2013, when they were eleven years old, the sixth sweep (MCS6) in 2015, when they were fourteen years old, and the seventh sweep (MCS7) in 2018, when they were seventeen years old.
End User Licence versions of MCS studies:
The End User Licence (EUL) versions of MCS1, MCS2, MCS3, MCS4, MCS5, MCS6 and MCS7 are held under UK Data Archive SNs 4683, 5350, 5795, 6411, 7464, 8156 and 8682 respectively. The longitudinal family file is held under SN 8172.

Sub-sample studies:
Some studies based on sub-samples of MCS have also been conducted, including a study of MCS respondent mothers who had received assisted fertility treatment, conducted in 2003 (see EUL SN 5559). Also, birth registration and maternity hospital episodes for the MCS respondents are held as a separate dataset (see EUL SN 5614).

Release of Sweeps 1 to 4 to Long Format (Summer 2020)To support longitudinal research and make it easier to compare data from different time points, all data from across all sweeps is now in a consistent format. The update affects the data from sweeps 1 to 4 (from 9 months to 7 years), which are updated from the old/wide to a new/long format to match the format of data of sweeps 5 and 6 (age 11 and 14 sweeps). The old/wide formatted datasets contained one row per family with multiple variables for different respondents. The new/long formatted datasets contain one row per respondent (per parent or per cohort member) for each MCS family. Additional updates have been made to all sweeps to harmonise variable labels and enhance anonymisation.

How to access genetic and/or bio-medical sample data from a range of longitudinal surveys:
For information on how to access biomedical data from MCS that are not held at the UKDS, see the CLS Genetic data and biological samples webpage.

Secure Access datasets:
Secure Access versions of the MCS have more restrictive access conditions than versions available under the standard End User Licence or Special Licence (see 'Access data' tab above).

Secure Access versions of the MCS...

This data package contains the hospital bed availability and occupancy data by consultant main specialty and sector as well as data on inpatient and outpatient related hospital activity in England. It also contains information on Sub-Saharan public hospitals.

This report contains generic information about pacing and ICD practice in the United Kingdom and Republic of Ireland up to and including 2000.

With healthcare database selections covering NHS Management, Doctors, General Practice, Dentists, Care Homes and Private Hospitals, contact lists can be purchased by job role, seniority level, size and region.

Characteristics of included studies assessing antipsychotic medications (n = 60).

Data for this publication are extracted each month as a snapshot in time from the Primary Care Registration database within the NHAIS (National Health Application and Infrastructure Services) system. This release is an accurate snapshot as at 1 April 2024. This publication also includes monthly data outputs from the Personal Demographic Service, which will become the data source for this publication from May 2024. More information about the data source change can be found in the Data Quality Statement. GP Practice; Primary Care Network (PCN); Sub Integrated Care Board Locations (SICBL); Integrated Care Board (ICB) and NHS England Commissioning Region level data are released in single year of age (SYOA) and 5-year age bands, both of which finish at 95+, split by gender. In addition, organisational mapping data is available to derive PCN; SICBL; ICB and Commissioning Region associated with a GP practice and is updated each month to give relevant organisational mapping. Quarterly publications in January, April, July and October will include Lower Layer Super Output Area (LSOA) populations.

We have worked with NHS Improvement (now NHS England) to produce a dataset on prescribing in a hospital setting which has been dispensed in the community. The data is related to items prescribed and dispensed in England. The data only includes items prescribed by NHS Hospital Trust Units which have been dispensed in the community. Cost Centre data is not included in this dataset. The data provided is based on England Hospital Trust prescribing only and may include items prescribed in England but dispensed in Wales, Scotland, Northern Ireland, Guernsey, Jersey, Alderney and the Isle of Man. The dataset excludes: • Items not dispensed, disallowed and those returned to the contractor for further clarification. • Prescriptions prescribed and dispensed in Prisons, Hospitals and Private prescriptions. • Items prescribed but not presented for dispensing or not submitted to NHS Prescription Services by the dispenser You can read more about dataset in the guidance document: Hospital prescribing dispensed in the community guidance (Word: 246KB) Notices 28 May 2024: We've updated our prescription data reports to reflect the recent changes to the discount deduction applied to pharmacy contractors monthly total of reimbursement prices, listed in the Drug Tariff Part V. For data from April 2024 (published in June) any financial report referencing actual cost includes discounts calculated according to the new methodology. You can find more details in this article: Changes to Actual Cost reporting calculation (Pharmacy only)

DECOVID, a multi-centre research consortium, was founded in March 2020 by two United Kingdom (UK) National Health Service (NHS) Foundation Trusts (comprising three acute care hospitals) and three research institutes/universities: University Hospitals Birmingham (UHB), University College London Hospitals (UCLH), University of Birmingham, University College London and The Alan Turing Institute. The original aim of DECOVID was to share harmonised electronic health record (EHR) data from UCLH and UHB to enable researchers affiliated with the DECOVID consortium to answer clinical questions to support the COVID-19 response.   ​​   ​​The DECOVID database has now been placed within the infrastructure of PIONEER, a Health Data Research (HDR) UK funded data hub that contains data from acute care providers, to make the DECOVID database accessible to external researchers not affiliated with the DECOVID consortium.  

This highly granular dataset contains 256,804 spells and 165,414 hospitalised patients. The data includes demographics, serial physiological measurements, laboratory test results, medications, procedures, drugs, mortality and readmission.

Geography: UHB is one of the largest NHS Trusts in England, providing direct acute services & specialist care across four hospital sites, with 2.2 million patient episodes per year, 2750 beds & > 120 ITU bed capacity. UCLH provides first-class acute and specialist services in six hospitals in central London, seeing more than 1 million outpatient and 100,000 admissions per year. Both UHB and UCLH have fully electronic health records. Data has been harmonised using the OMOP data model. Data set availability: Data access is available via the PIONEER Hub for projects which will benefit the public or patients. This can be by developing a new understanding of disease, by providing insights into how to improve care, or by developing new models, tools, treatments, or care processes. Data access can be provided to NHS, academic, commercial, policy and third sector organisations. Applications from SMEs are welcome. There is a single data access process, with public oversight provided by our public review committee, the Data Trust Committee. Contact pioneer@uhb.nhs.uk or visit www.pioneerdatahub.co.uk for more details.

Available supplementary data: Matched controls; ambulance and community data. Unstructured data (images). We can provide the dataset in other common data models and can build synthetic data to meet bespoke requirements.

Available supplementary support: Analytics, model build, validation & refinement; A.I. support. Data partner support for ETL (extract, transform & load) processes. Bespoke and “off the shelf” Trusted Research Environment (TRE) build and run. Consultancy with clinical, patient & end-user and purchaser access/ support. Support for regulatory requirements. Cohort discovery. Data-driven trials and “fast screen” services to assess population size.

Data identifying the location of NHS Regions. For more information, please see the ONS Geoportal website.

Boundaries for these geographies have been generalised (to 20 metres) and clipped. You can find further information on these formats in the downloadable Boundary Guidance document on the Open Geography portal.

When using boundary data, please acknowledge the copyright and the source of the data by including the following attribution statements:

Contains National Statistics data © Crown copyright and database right (2016)

Contains OS data © Crown copyright and database right (2016)

For more details about licencing go to: https://www.ons.gov.uk/methodology/geography/licences

All data is correct as of download date: 21/11/2016

Full details of every data item available on both the Maternity Indicators dataset and National Community Child Health Database are available through the NWIS Data Dictionary: http://www.datadictionary.wales.nhs.uk/#!WordDocuments/datasetstructure20.htm From 1st April 2019 health service provision for residents of Bridgend local authority moved from Abertawe Bro Morgannwg to Cwm Taf. For more information see the joint statement from Cwm Taf and Abertawe Bro Morgannwg University Health Boards (see weblinks). The health board names have changed with Cwm Taf University Health Board becoming Cwm Taf Morgannwg University Health Board and Abertawe Bro Morgannwg University Health Board becoming Swansea Bay University Health Board. Data for Abertawe Bro Morgannwg and Cwm Taf are available for previous years in this table by selecting the tick boxes in the Area drop-down box.

Outcomes and measures for assessing psychotic symptoms in included studies.

Could I please request the prescribing data for unlicensed cannabis based medicinal products [CBMP] prescribed privately, from Nov 2018 until the most recent available. I'm particularly looking for the item count, broken down on a monthly basis. Response A copy of the information is attached. Private prescribing of unlicensed cannabis-based medicines November 2018 to March 2023 NHS Prescription Services, within the NHS Business Services Authority (NHSBSA) process prescriptions for Pharmacy Contractors, Appliance Contractors, Dispensing Doctors and Personal Administration. This information is then used to make payments to pharmacists and appliance contractors in England for prescriptions dispensed in primary care settings. There are other arrangements in place for making payments to Dispensing Doctors and Personal Administration. This involves processing over 1 billion prescription items and payments totalling over £9 billion each year. The information gathered from this process is then used to provide information on costs and trends in prescribing in England and Wales to over 25,000 registered NHS and Department of Health and Social Care users. Data Source When prescriptions are processed by the NHSBSA data capture, prescriptions sometimes contain prescribing of medicines that were not populated on the NHSBSA drug database at the time. This type of order will be captured as an ‘unspecified drug.’ Data for prescribing of unlicensed cannabis-based medicines has been taken from data captured as unspecified prescribing. Unlicensed cannabis-based medicines are identified by an additional review process which occurs after the prescriptions have been processed. The items identified by this review are reported against the date that the prescription was written and not necessarily when they were submitted. Therefore, these figures may be subject to change if the prescription is submitted to the NHSBSA in a later month. This dataset This dataset shows total items per month for private prescriptions for unlicensed cannabis-based products. Time Period November 2018 to March 2023 (the latest available month currently). The Data is presented monthly. Organisation Data Data for private unlicensed prescriptions is limited to prescriptions dispensed in England. Items Shows the number of times a product appears on a prescription form not the quantity prescribed.